- Joined
- 2 May 2007
- Posts
- 4,688
- Reactions
- 2,901
A2M is still in deep wood??
So is it becoming a buy? The company appears ripe for takeover by a Chinese company.A2M share action in New Zealand this morning at about 10:30 AM
View attachment 137867
ASX ANNOUNCEMENTS TODAY
View attachment 137868
A2 Milk share price on watch after posting big earnings decline
- Revenue down 2.5% over the prior corresponding period to NZ$661 million
- EBITDA down 45.3% to NZ$98 million
- Net profit after tax down 53.3% to NZ$56 million
- Net cash of NZ$667 million
What happened during the first half?
For the six months ended 31 December, A2 Milk reported a 2.5% decline in revenue to NZ$661 million. This was driven by a 10.5% reduction in infant nutrition revenue to NZ$471 million, a 0.2% lift in Liquid milk revenue to NZ$125 million, and a 143.3% jump in other revenue to NZ$65 million. Other revenue includes revenue from its Mataura Valley Milk (MVM) business, which was acquired at the end of FY 2021. MVM revenue was down 8.2% year on year.
Management advised that its first half revenue was impacted by a number of factors, including the lower birth rate and rapidly changing market dynamics in China.
As was widely expected, A2 Milk’s margins were crunched during the period. Management advised that this reflects gross margin pressures, such as adverse product mix and cost headwinds, together with higher marketing investments. The latter ultimately led to the company’s EBITDA margin falling to a lowly 14.8%.
As a result, the company posted a 53.3% decline in net profit after tax to NZ$56.1 million. This has fallen short of the market consensus estimate of NZ$60 million, which may not bode well for the A2 Milk share price today.
Management commentary
Despite this poor result, A2 Milk Company’s Managing Director and CEO, David Bortolussi, believes the company is making progress:
He said: “Despite challenging market conditions in China and COVID-19 volatility, we are making good progress stabilising the business. The growth strategy we announced in October last year to respond to a rapidly changing China market has been completed and implementation is underway with good early progress across a range of initiatives.”
“We remain confident in the long-term China infant milk formula market, and we are growing share in our China label business in-store and online with strong consumer offtake and share growth. The actions we took to address excess infant milk formula inventory last year are proving effective, and we are seeing improvements in English label channel inventory levels, market pricing and product freshness.”
While English label sales were down during the half, we have seen an improvement in trajectory in the ANZ reseller / daigou channel. Our brand health is strong, and we will continue to increase brand investment, content generation, and activation to drive awareness and conversion,” Bortolussi concluded.
Outlook
Due to the uncertainty the company is facing, it is not providing any guidance for FY 2022. However, it has provided observations on key drivers and important issues that may impact its results.
And while management believes that its revenue could be stronger in the second half, this won’t necessarily translate into stronger earnings.
It explained: “The Company’s outlook for 2H22 revenue has improved. It is still expected to be significantly higher than 2H21, and with growth now expected on 1H22 and for FY22, ahead of initial expectations due mainly to growth in China label and English label IMF. However, this revenue improvement is not expected to translate into higher earnings as the Company significantly increases brand and other reinvestment consistent with its growth strategy.”
FY 2022’s marketing investment is now expected to be in the order of NZ$220 million, which is higher than FY 2020 peak levels. This is being done to drive the execution of its growth strategy.
I agree ripe for a takeover, but I dont think NZ would let there biggest agricultural company go in to the hands of foreign ownership.So is it becoming a buy? The company appears ripe for takeover by a Chinese company.
A baby-formula shortage feeds criticism of corporate heft and price gouging
The former is a valid concern. The latter is a misleading distraction
Throughout the pandemic shoppers have learned again and again about the fragility of supply chains. In America the latest product missing from supermarket shelves is infant formula. Whereas previous shortages, affecting everything from cars to couches, presented an inconvenience to consumers, a lack of nourishment for babies creates serious health risks. So the Biden administration has swung into action. On May 16th the Food and Drug Administration (fda) announced that America would loosen restrictions on imports of formula from other countries and take steps to increase domestic production.
There are several overlapping explanations for the shortage. The biggest single
A baby-formula shortage feeds criticism of corporate heft and price gouging
The former is a valid concern. The latter is a misleading distractionwww.economist.com
Third class action launched against A2 Milk after share price crash
Trans-Tasman dairy company A2 Milk says it will “vigorously defend” an investor class action that alleges it gave misleading guidance ahead of a spectacular share price crash.
Thorn Law launched proceedings in the Auckland High Court on Wednesday on behalf of investors who are seeking compensation after suffering losses from a “significant decline” in the value of A2 Milk shares between August 19, 2020 and May 9, 2021.
During that time, A2’s shares more than halved to about $7. They have since plummeted further to $4.15 at Wednesday’s close – far off their peak of almost $20 in July 2020.
It is the third class action lobbed against the company, which has maintained it complied with its disclosure obligations “at all times”.
A2 has been struggling to recover from the Covid-fuelled collapse of the lucrative Chinese daigou – or reseller market.
At the same time, it has had significant management changes, with three chief executives in the past three years. Senior executives including its chief financial officer, Asia Pacific boss, chief technology officer and corporate affairs director have also left the company
Market cap is $3.6B so divide the buyback by that to get the "yield".Bit of a noobish question but how much will a 133.6 million dollar buy back actually have on the share price in your opinion?
Not alot unless it's done at savvy occasions.Bit of a noobish question but how much will a 133.6 million dollar buy back actually have on the share price in your opinion?
Yeah, but.
Highly variable market and time wise.
"The buyback programme is expected to commence towards the end of September 2022 and may run for up to 12 months.
The Company may acquire shares through the NZX and ASX at the prevailing market price from time to
time in that period."
Not alot unless it's done at savvy occasions.
General up draught.
To me, the wording is "positive".
The SP rise "how much" in reality can't be quantified, only the representative "yield" as per io'boy post.
Thanks @bigdog for sharing the FDA approval news.View attachment 148768
NZX Code: ATM
ASX Code: A2M
3 November 2022
NZX/ASX Market Release
FDA approval to supply infant milk formula to the United States
The a2 Milk Company (a2MC, the Company) advises that the United States (US) Food and Drug Administration (FDA) has notified the Company that it has exercised its discretion to allow a2MC to import infant milk formula (IMF) products into the US.
Following the onset of IMF supply disruption in the US, FDA Guidance was released on 16 May 2022 in relation to case-by-case consideration of enforcement discretion to be applied to companies with the goal of increasing IMF supplies. a2MC applied to the FDA on 26 May 2022 under its enforcement discretion to supply IMF to the US. As
announced by the Company on 10 August 2022, the FDA had deferred further consideration of a2MC’s application for enforcement discretion. However, the Company has continued to engage with the FDA to meet its requirements and to reconsider a2MC’s application.
Pleasingly the Company has today received confirmation from the FDA that its application for enforcement discretion to import, sell and distribute a2 Platinum® IMF product (Stages 1 and 2) from New Zealand into the US has been approved through to 6 January 2023. The Company is also able to supply Stage 3 toddler product in addition to this which does not require enforcement discretion.
New Zealand share price up 7.3% at 10:30 AM NZ time this morning
View attachment 148769
Opportunity to export to India- largest populationBirth rate is increasing in Australia, more births, more formula, I also believe that Australia china trade relations are improving in the short term, hopefully we will see a further opening of the Daigou, I think it is also important to remember Nestle and others have looked at acquiring A2M in the past, no reason speculation couldn't start again in the next 12 months. A bit of a punt on this one.
Hello and welcome to Aussie Stock Forums!
To gain full access you must register. Registration is free and takes only a few seconds to complete.
Already a member? Log in here.